
Results 1 - 20 of 29 in Amaryl, Glimepiride (generic)
New Study Results Show That Patients Have Higher Treatment...
MONTREAL, Oct. 22 /CNW/ - New data on patient treatment satisfaction from the LEAD 6 trial presented on the 22nd October at the 20th World Diabetes Congress shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide. Comment?
Diabetes drugs may leave heart at greater risk
Medications for Type 2 diabetes are very effective at controlling blood sugar levels. Comment?
New Study Results Show That Patients Have Higher Treatment...
To view the Multimedia News Release, please click: Specifically, among the 379 patients who completed the Diabetes Treatment Satisfaction Questionnaires during the LEAD 6 trial, those taking liraglutide perceived less hypoglycaemia or hyperglycaemia compared to those on exenatide. Comment?
Sulfonylureas May Elevate Risk in MI Survivors (MI as in myocardial...
Four widely prescribed oral sulfonylurea drugs are associated with significantly increased risk of all-cause mortality compared with metformin in type 2 diabetic patients having a history of MI, according to a comprehensive Danish national cohort study. Comment?
A class of diabetes drugs sometimes called “starch blockers” that blocks the action of enzymes that normally begin to break down certain carbohydrates in the upper part of the small intestine. Comment?
New Data Shows That Type 2 Diabetes Patients Who Start Insulin...
Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix 30 achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine. Comment?
A condition in which the body needs extra insulin to maintain normal blood sugar levels. Comment?
Archive for August 5th, 2009 El Paso taquerias, a sizzling success El Paso taquerias, a sizzling success The terrace at the new El Paso Taqueria. Comment?
Novo Nordisk study finds once-daily liraglutide reduces blood sugar, weight in African-Americans
LAS VEGAS A study by Novo Nordisk concluded that once-daily liraglutide, an investigational treatment for Type 2 diabetes, leads to statistically significant and sustained reductions in blood sugar and weight in African-Americans with Type 2 diabetes, as compared with glimepiride, a commonly prescribed diabetes treatment. Comment?
Novo Nordisk study finds once-daily liraglutide reduces blood sugar, weight in African-Americans
LAS VEGAS A study by Novo Nordisk concluded that once-daily liraglutide, an investigational treatment for Type 2 diabetes, leads to statistically significant and sustained reductions in blood sugar and weight in African-Americans with Type 2 diabetes, as compared with glimepiride, a commonly prescribed diabetes treatment. Comment?
Liraglutide Lowered Blood Sugar and Weight in African Americans With...
The data were presented at the 114th National Medical Association Annual Convention & Scientific Assembly. Comment?
Liraglutide Lowered Blood Sugar and Weight in African Americans With...
The data were presented at the 114th National Medical Association Annual Convention & Scientific Assembly. Comment?
Diabetic Claims Jail Did Not Give Needed Medication
Gary Arrington, 45, of Whitesboro spent two days in Cape May County Jail on a contempt charge for child support, and claimed during that time, he was not allowed to take medications for his diabetes and back pain. Comment?
Two-Year Data Show Investigational Drug Liraglutide More Effective at ...
Novo Nordisk data presented at the 69th Annual Scientific Sessions of the American Diabetes Association showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight after two years of treatment. Comment?
New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial...
Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual Meeting show clinically relevant and statistically significant reductions in haemoglobin A1c and fasting plasma glucose levels when linagliptin, a dipeptidyl peptidase 4 inhibitor, is given as add-on therapy in Type 2 diabetic ... Comment?
New Diabetes Drug Shows Promise in Trial
An experimental diabetes drug called liraglutide appears to outperform exenatide , the only currently approved drug in its class, a study funded by liraglutide's maker, Novo Nordisk, shows. Comment?
New Diabetes Drug Shows Promise in Trial
An experimental diabetes drug called liraglutide appears to outperform exenatide , the only currently approved drug in its class, a study funded by liraglutide's maker, Novo Nordisk, shows. Comment?
New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial...
Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual Meeting show clinically relevant and statistically significant reductions in haemoglobin A1c and fasting plasma glucose levels when linagliptin, a dipeptidyl peptidase 4 inhibitor, is given as add-on therapy in Type 2 diabetic ... Comment?
Boehringer Ingelheim Unveils Diabetes Pipeline
Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area. Comment?
Study finds Novo Nordisk diabetes drug works better than original
NEW ORLEANS Results of a phase 3 study presented Sunday at the American Diabetes Associationa s 69th annual scientific sessions indicates that an investigational diabetes drug works better than a drug originally made by Sanofi-Aventis. Danish drug maker Novo Nordisk presented data showing that liraglutide was more effective at lowering blood sugar ... Comment?